Micell Technologies Rapid Absorption Polymer DES System to be Presented at CRT 2009

RALEIGH, N.C., March 4 /PRNewswire/ -- Micell Technologies announced today that David E. Kandzari, MD, will present "The Micell Rapid Absorption Polymer DES System" during the Cardiovascular Research Technologies (CRT) meeting in Washington, DC, on March 5, 2009. MiStent(TM), a Drug-Eluting Stent (DES) in pre-clinical studies, utilizes a bioasorbable polymer coating that delivers the potential benefits of the drug during the healing process. The proprietary formulation allows the polymer to be absorbed concurrent with the drug delivery rather than sequentially like other absorbable DES coatings. This allows both the polymer and drug to be eliminated within 90 days and provides the potential for improved patient benefits.

"The Micell DES technology is exciting because it is the first of a new generation of stents being developed to precisely deliver a drug while safely eliminating the polymer faster than any other bioabsorbable coating that is commercially available," said Kandzari. "The unique formulation that allows the polymer to be absorbed at the same time that the drug is being delivered offers the therapeutic benefits of a drug-eluting stent, while quickly transforming itself to the safety profile of a bare metal stent."

Earlier this year, Micell obtained the rights to a CE marked cobalt chromium stent to use as its platform for its proprietary coating. Arthur J. Benvenuto, Chairman and Chief Executive Officer of Micell, said, "The pieces are quickly coming together as we demonstrate the advantages of our proprietary formulation and deliver it on a state-of-the-art stent with the lowest strut thickness commercially available. Our scalable drug and polymer coating process serves as a platform for the development of innovative interventional cardiology systems."

Dr. Kandzari is the Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, CA.

About Micell Technologies Inc.

Micell Technologies is a privately-held, development-stage biomedical device company dedicated to developing innovative interventional cardiology systems. By applying its unique surface and polymer modification technologies, Micell can precisely and consistently control drug elution and the duration of polymer exposure creating the potential for a therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Its first product in development, MiStent(TM), is a rapid absorbing coated drug-eluting stent with precise control of drug release and pharmacokinetics. Visit us at www.micell.com.

CONTACT: Arthur J. Benvenuto, Chairman & CEO of Micell Technologies,
+1-919-313-2104

Web site: http://www.micell.com/

Back to news